Eletriptan (Relpax)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Migraine

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Latest reported trial: NCT01978496 · Phase 3 · met primary endpoint · grade pending

Also approved (1)
JP
  • Acute treatment of migraine (Relpax tablets 20 mg; approval number 21400AMZ00463)
Product first approved 2002PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (6)
Migraine
NCT00385008 · GlaxoSmithKline
2006-09-13 – 2006-11-24 · Migraine Disorders
What this study did
NCT01989936 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
1999-01 – 2000-09 · Migraine With or Without Aura
What this study did
NCT01986270 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
1996-12 – 1998-01 · Migraine With or Without Aura
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT06677229 · Technophage, SA
2025-08-01 – 2027-06 · Acute Spinal Cord Injury (SCI)
What this study did
Phase 1 (2)
Other / comorbidity
NCT01139515 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2010-07 – 2010-07 · Healthy
What this study did
NCT00871806 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009-04 – 2009-04 · Healthy Volunteers
What this study did
Phase 4 (4)
Migraine
NCT00259649 · University of Pittsburgh
2004-08 – 2008-08 · Migraine
What this study did
NCT00174395 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005-03 – 2006-10 · Migraine
What this study did
NCT00634985 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2002-11 – 2003-12 · Migraine
What this study did
NCT00632385 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2003-01 – 2003-08 · Migraine
What this study did
Early phase / not applicable (1)
Migraine
NCT01276977 · California Medical Clinic for Headache
2008-04 – 2010-12 · Acute Migraine, Migraine Headache, Headache Disorders
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Migraine
NCT00751803 · Boehringer Ingelheim
2008-08 – 2009-05 · Migraine Disorders
What this study did

Competitive landscape

This mechanism is crowded: 17 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Migraine: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Eletriptan (Relpax): this drugApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Aspirin / Acetaminophen / Caffeine (Excedrin Migraine)Approved—Nonsteroidal Anti-inflammatory Drug, Adenosine receptornot yet gradedNo reviewed efficacy summary in this indication
Atogepant (Qulipta)ApprovedSmall moleculeCGRP receptorReliable signal
NCT03777059: Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Placebo -2.48 migraine days per month (Standard Error 0.21) | Atogepant 10 mg -3.69 migraine days per month (Standard Error 0.21) | Atogepant 30 mg -3.86 migraine days per month (Standard Error 0.206) | Atogepant 60 mg -4.2 migraine days per month (Standard Error 0.206)
NCT02848326: Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period (Baseline (First 28 Days of Screening/Baseline Period) to Week 12): Placebo -2.85 migraine days per month (Standard Error 0.23) | Atogepant 10 mg QD -4 migraine days per month (Standard Error 0.32) | Atogepant 30 mg QD -3.76 migraine days per month (Standard Error 0.23) | Atogepant 60 mg QD -3.55 migraine days per month (Standard Error 0.23) | Atogepant 30 mg BID -4.23 migraine days per month (Standard Error 0.35) | Atogepant 60 mg BID -4.14 migraine days per month (Standard Error 0.33)
Celecoxib (Elyxyb)ApprovedSmall moleculeCOX-2Partial signalNo reviewed efficacy summary in this indication
Diclofenac Potassium (Cambia)ApprovedSmall moleculeNonsteroidal Anti-inflammatory Drugnot yet gradedNo reviewed efficacy summary in this indication
Dihydroergotamine (Atzumi)ApprovedSmall molecule5-HT1D receptorPartial signal
NCT04940390: Co-primary endpoints at 2 hours, STS101 5.2 mg (n=716) vs placebo (n=708), mITT: freedom from pain 146/716 (20.4%) vs 124/708 (17.5%); freedom from most bothersome symptom 265/716 (37.0%) vs 230/708 (32.5%). The sponsor states the differences did not reach statistical significance; no p-values are reported. missed
NCT03901482: Co-primary endpoints at 2 hours, STS101 3.9 mg (n=354) and 5.2 mg (n=353) vs placebo (n=358), mITT: freedom from pain 69/354 (19.5%) and 68/353 (19.3%) vs 53/358 (14.8%); freedom from most bothersome symptom 133/354 (37.6%) and 139/353 (39.4%) vs 119/358 (33.2%). The sponsor states neither dose was statistically significant on either co-primary endpoint; no p-values are reported. missed
Dihydroergotamine Mesylate (Brekiya)ApprovedSmall molecule5-HT1D receptornot yet gradedNo reviewed efficacy summary in this indication
Dihydroergotamine Mesylate (D.H.E. 45)
ApprovedUS marketing discontinued
Small molecule5-HT1D receptornot yet gradedNo reviewed efficacy summary in this indication
Dihydroergotamine Mesylate (Migranal)ApprovedSmall molecule5-HT1D receptornot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eptinezumab (Vyepti)ApprovedMonoclonal antibodyCGRP ligandReliable signal
NCT02974153: Change From Baseline in Monthly Migraine Days (Week 1-12): 300 mg ALD403 -8.2 Migraine Days (range -23 to 11) | 100 mg ALD403 -7.7 Migraine Days (range -22 to 10) | Placebo -5.6 Migraine Days (range -25 to 9)
NCT02559895: Change From Baseline in Monthly Migraine Days (Weeks 1-12) (Week 1-12): 300 mg ALD403 -4.3 Migraine Days (Standard Deviation 3.42) | 100 mg ALD403 -3.9 Migraine Days (Standard Deviation 3.23) | 30 mg ALD403 -4.1 Migraine Days (Standard Deviation 3.22) | Placebo -3.1 Migraine Days (Standard Deviation 3.7)
Erenumab (Aimovig)ApprovedMonoclonal antibodyCGRP receptorReliable signal
NCT03867201: Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45)
NCT02456740: Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period (4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase): Placebo -1.83 migraine days / month (Standard Error 0.18) | Erenumab 70 mg QM -3.23 migraine days / month (Standard Error 0.18) | Erenumab 140 mg QM -3.67 migraine days / month (Standard Error 0.18)
Ergotamine / Caffeine (Cafergot)
ApprovedUS marketing discontinued
Small moleculeAlpha-adrenergic receptor, Adenosine receptornot yet gradedNo reviewed efficacy summary in this indication
Fremanezumab (Ajovy)ApprovedMonoclonal antibodyCGRP ligandPartial signal
NCT04458857: Change in monthly migraine days over 12 weeks: fremanezumab -2.5 vs placebo -1.4; LS mean difference -1.0 (95% CI -1.90 to -0.16), p=0.0210 (n=123 and 111) (CT.gov posted results).
NCT02621931: Change in monthly headache days of at least moderate severity over 12 weeks (median): fremanezumab 675 mg quarterly -4.2 (n=375) and 675/225/225 mg monthly -4.5 (n=375) vs placebo -2.5 (n=371); LS mean difference from placebo -1.8 (95% CI -2.46 to -1.15) and -2.1 (95% CI -2.76 to -1.45), both p < 0.0001 (Wilcoxon) (CT.gov posted results).
Frovatriptan (Frova)
ApprovedUS marketing discontinued
Small molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Galcanezumab (Emgality)ApprovedMonoclonal antibodyCGRP ligandReliable signal
NCT03963232: Change in monthly migraine headache days over 3 months, LS mean -3.81 (galcanezumab 120 mg) vs -1.99 (placebo); difference -1.82 days (95% CI -2.32 to -1.32), p<.0001.
NCT03559257: Change in monthly migraine headache days over months 1 to 3 (treatment-resistant migraine), LS mean -4.14 (galcanezumab 120 mg) vs -1.02 (placebo); difference -3.12 days (95% CI -3.92 to -2.32), p<0.0001.
Ibuprofen (Advil Migraine)ApprovedSmall moleculeNonsteroidal Anti-inflammatory Drugnot yet gradedNo reviewed efficacy summary in this indication
Meloxicam / Rizatriptan (Symbravo)ApprovedSmall molecule5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory DrugReliable signalFeatured results are safety only in this race
Naratriptan (Amerge)
ApprovedUS marketing discontinued
Small molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
onabotulinumtoxinA (Botox)ApprovedBiologic (subtype unspecified)Acetylcholine Release Inhibitor, acetylcholine releasenot yet gradedNo reviewed efficacy summary in this indication
Propranolol (Inderal LA)ApprovedSmall moleculeBeta-1/beta-2 adrenergic receptorsnot yet gradedNo reviewed efficacy summary in this indication
Rimegepant (Nurtec ODT)ApprovedSmall moleculeCGRP receptorReliable signal
NCT05810038: Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14)
NCT05399485: Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase (Baseline, Week 9 to Week 12 of the DBT phase): Rimegepant -2.4 Days/month (95% CI -2.93 to -1.96) | Placebo -1.4 Days/month (95% CI -1.87 to -0.91)
Rizatriptan (Maxalt)ApprovedSmall molecule5-HT1B/1D receptorPartial signalFeatured results are non-efficacy only in this race
Rizatriptan (RizaFilm)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan (Onzetra Xsail)
ApprovedUS marketing discontinued
Small molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan (Tosymra)ApprovedSmall molecule5-HT1B/1D receptorWeak signalFeatured results are safety only in this race
Sumatriptan Succinate (Sumavel DosePro)
ApprovedUS marketing discontinued
Small molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate (Zembrace SymTouch)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate Injection (Imitrex)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate Nasal Spray (Imitrex)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate Tablets (Imitrex)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan / Naproxen Sodium (Treximet)ApprovedSmall molecule5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory DrugWeak signalNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00236509: Primary endpoint, change in mean 4-week migraine frequency (baseline to double-blind phase, ITT n=469): -1.3, -2.1 and -2.2 with topiramate 50, 100 and 200 mg/day vs -0.8 with placebo; 100 and 200 mg/day vs placebo p<0.001 (TOPAMAX label, Study 11 = TOPMAT-MIGR-001).
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Ubrogepant (Ubrelvy)ApprovedSmall moleculeCGRP receptorReliable signal
NCT04492020: Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Placebo 121 Participants | Ubrogepant 100 mg 190 Participants
Zavegepant (Zavzpret)ApprovedSmall moleculeCGRP receptorReliable signalNo reviewed efficacy summary in this indication
Zolmitriptan (Zomig Nasal Spray)ApprovedSmall molecule5-HT1B/1D receptorsnot yet gradedNo reviewed efficacy summary in this indication
Almotriptan (Axert)US approval withdrawnSmall molecule5-HT1B/1D receptorWeak signalNo reviewed efficacy summary in this indication
ElismetrepPhase 3—TRPM8not yet gradedNo reviewed efficacy summary in this indication
IncobotulinumtoxinA (Xeomin)Phase 3Protein / enzyme therapeuticacetylcholine releasenot yet gradedNo reviewed efficacy summary in this indication
Rizatriptan / NaproxenPhase 3Small molecule5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory Drugnot yet gradedNo reviewed efficacy summary in this indication
Naltrexone / Acetaminophen (ALLOD-2)Phase 2/3—Opioid receptornot yet gradedNo reviewed efficacy summary in this indication
BHV-2100Phase 2—TRPM3not yet gradedNo reviewed efficacy summary in this indication
EVO756Phase 2Small moleculeMRGPRX2not yet gradedNo reviewed efficacy summary in this indication
ABBV-2002
—(overall)
UndisclosedPAR-2not yet gradedNo reviewed efficacy summary in this indication
Dihydroergotamine Mesylate / Dipyrone / Caffeine (Cefaliv)
—(overall)
—5-HT1D receptor, Adenosine receptornot yet gradedNo reviewed efficacy summary in this indication
Dipyrone / Isometheptene Mucate / Caffeine (Neosaldina)
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Lasmiditan (Reyvow)DiscontinuedSmall molecule5-HT1F receptorReliable signalNo reviewed efficacy summary in this indication
Propranolol (Inderal)DiscontinuedSmall moleculeBeta-1/beta-2 adrenergic receptorsnot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate (Zecuity)DiscontinuedSmall molecule5-HT1B/1D receptorPartial signalFeatured results are non-efficacy and safety only in this race
Sumatriptan Succinate Auto-Injector (Alsuma)DiscontinuedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Zolmitriptan (Zomig)DiscontinuedSmall molecule5-HT1B/1D receptorsnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Eletriptan (Relpax) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1/2Acute Spinal Cord Injury (SCI)Recruiting
Est. primary completion 2026-12 · NCT06677229 · CT.gov ↗
What to watch

See the full readout calendar ↗